Jean-Christophe Leroux
Keine laufenden Positionen mehr
Profil
Jean-Christophe Leroux is associated with two companies, Inositec AG and Versantis AG, both of which he founded in 2015.
Ehemalige bekannte Positionen von Jean-Christophe Leroux
| Unternehmen | Position | Ende |
|---|---|---|
Versantis AG
 Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | Gründer | - |
Inositec AG
 Inositec AG Pharmaceuticals: MajorHealth Technology Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Inositec AG
Inositec AG Pharmaceuticals: MajorHealth Technology Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland. | Health Technology |
Versantis AG
Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | Health Technology |
